BioNTech’s Patent Suit Looms as Moderna Pays $950M to Settle COVID-19 Disputes
BioNTech SE filed a patent infringement lawsuit in February, claiming Moderna’s mNEXSPIKE relies on its proprietary lipid nanoparticle technology. Moderna’s $950 million COVID-19 litigation settlement with Arbutus and Roivant clears overhang but leaves BioNTech’s suit as the next legal catalyst.
1. BioNTech’s Patent Infringement Claim
In February, BioNTech SE filed a lawsuit against Moderna alleging that Moderna’s mNEXSPIKE COVID-19 vaccine uses lipid nanoparticle technology patented by BioNTech. The complaint seeks compensation for alleged patent violations and requests injunctive relief against further sales.
2. Moderna’s $950M Settlement Impact
Moderna agreed to pay $950 million in Q3 to resolve all litigation with Arbutus Biopharma and Roivant’s Genevant Sciences over its Spikevax and mRESVIA products. This resolution clears a legal backlog, allowing Moderna to reallocate resources toward its defense of BioNTech’s pending suit.
3. Potential Leverage for BioNTech
With Moderna’s cash earmarked for the settlement, BioNTech may gain negotiating leverage for higher damages or faster resolution in its case. The pending lawsuit could command payments up to several hundred million dollars, depending on court findings and potential appeals.
4. Outlook for BioNTech’s Litigation
BioNTech’s case is expected to proceed through pretrial motions this year, with trial dates potentially set in late 2026. Investors will monitor any shifts in Moderna’s litigation budget and court filings for signs of a settlement trajectory or trial outcome.